Skip to main content
. Author manuscript; available in PMC: 2013 Feb 3.
Published in final edited form as: Nat Genet. 2009 Sep 20;41(10):1122–1126. doi: 10.1038/ng.448

Table 2. Association results from a GWAS in Iceland for variants reported to confer risk of prostate cancer identified through GWAS.

Marker, [risk allele] and (correlated
marker(s))a 		Locus Cases
(N)		 Controls
(N)		 Frequency
 OR (95% CI) P-value
Cases Controls
rs2710646 [A], (rs721048)6 2p15 1,882 35,145 0.224 0.203 1.14 (1.05, 1.24) 2.5×10−3
rs2660753 [T]4 3p12 1,725 35,362 0.110 0.100 1.11 (0.99, 1.25) 0.075
rs401681 [C]17 5p15 1,962 35,400 0.562 0.547 1.07 (1.00, 1.14) 0.066
rs9364554 [T]4 6q25 1,725 35,399 0.322 0.309 1.06 (0.99, 1.15) 0.11
rs10486567 [G]5 7p15 1,725 35,392 0.787 0.765 1.13 (1.04, 1.24) 4.4×10−3
rs6465657 [C]4 7q21 1,724 35,358 0.432 0.421 1.04 (0.97, 1.12) 0.26
rs1447295 [A]9 8q24 (1) 1,821 35,470 0.165 0.111 1.58 (1.43, 1.74) 2.2×10−19
rs16901979 [A]1 8q24 (2) 1,726 35,403 0.073 0.042 1.80 (1.55, 2.09) 2.5×10−14
rs6983267 [G]7 8q24 (3) 1,724 35,367 0.581 0.551 1.13 (1.05, 1.22) 7.5×10−4
rs1571801 [A]15 9q33 b 1,721 35,303 0.261 0.276 0.93 (0.85, 1.01) 0.068
rs10993994 [T]4,5 10q11 1,727 35,397 0.410 0.384 1.11 (1.04, 1.20) 3.7×10−3
rs4962416 [C]5 10q26c 1,724 35,322 0.223 0.221 1.02 (0.94, 1.11) 0.68
rs10896450 [G], (rs108964495, rs793 13424) 11q13 1,951 35,394 0.501 0.469 1.13 (1.06, 1.21) 2.5×10−4
rs4430796 [A]3 17q12 1,726 35,397 0.559 0.517 1.19 (1.10, 1.28) 8.3×10−6
rs11649743 [G]18 17q12 1,747 35,405 0.812 0.799 1.09 (0.99, 1.19) 0.066
rs1859962 [G]3 17q24.3 1,746 35,124 0.493 0.455 1.16 (1.08, 1.25) 3.7×10−5
rs2735839 [G]4 19q13.33 1,726 35,376 0.879 0.865 1.14 (1.02, 1.27) 0.021
rs9623117 [C]19 22q13 b 1,724 35,389 0.208 0.208 1.00 (0.91, 1.10) 0.99
rs5945572 [A]6, (rs5945 6194) Xp11 1,899 35,384 0.416 0.369 1.22 (1.11, 1.34) 6.1×10−5
a

Shown in the table are GWAS from Iceland for variants that have been identified through GWAS results (published up to February 2009) and the original publication(s). Highly correlated markers are shown in parenthesis as well as the study reporting them. All P values are two-sided. Shown are the corresponding numbers of cases and controls (N), allelic frequencies of variants in affected and control individuals, the allelic odds-ratio (OR) with 95% confidence interval (95% CI) and P value adjusted for relatedness.

b

The original results published for the loci on 9q3315 and 22q1319 were from a study on cases with aggressive prostate cancer. Results for these two loci in Icelandic cases (N = 693) with more aggressive prostate cancer (Gleason score >6 and/or T3 or higher and/or node positive and/or metastatic disease), using the same set of controls, were not significant (rs1571801; ORaggr = 0.90 and P = 0.080, rs9623117; ORaggr = 1.00 and P = 0.94).

c

The SNP marker, rs4962416, at the 10q26 locus is not on the Illumina Hap300 chip, results shown for it are based on a weighted combination of two marker haplotype generated from rs7077275 and rs893856 that are present on the chip and tag the SNP (rs4962416).